- cafead May 29, 2024 at 12:12: PM
via Merck announced on Wednesday it is acquiring privately held biotech EyeBio in a potential $3 billion bid to diversify its pipeline and reestablish itself as a major player in the ophthalmology space.
Under the terms of the agreement, Merck will pay $1.3 billion upfront and put $1.7 billion on the line in developmental, regulatory and commercial milestones. The acquisition has been unanimously approved by the EyeBio Board of Directors. Merck will carry out the purchase through a subsidiary.
article source
Under the terms of the agreement, Merck will pay $1.3 billion upfront and put $1.7 billion on the line in developmental, regulatory and commercial milestones. The acquisition has been unanimously approved by the EyeBio Board of Directors. Merck will carry out the purchase through a subsidiary.
article source